WO2007145318A1 - Sparc由来の癌拒絶抗原ペプチド及びこれを含む医薬 - Google Patents
Sparc由来の癌拒絶抗原ペプチド及びこれを含む医薬 Download PDFInfo
- Publication number
- WO2007145318A1 WO2007145318A1 PCT/JP2007/062117 JP2007062117W WO2007145318A1 WO 2007145318 A1 WO2007145318 A1 WO 2007145318A1 JP 2007062117 W JP2007062117 W JP 2007062117W WO 2007145318 A1 WO2007145318 A1 WO 2007145318A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- cells
- cancer
- cell
- sparc
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 141
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 96
- 201000011510 cancer Diseases 0.000 title claims abstract description 59
- 108091007433 antigens Proteins 0.000 title description 24
- 102000036639 antigens Human genes 0.000 title description 24
- 239000000427 antigen Substances 0.000 title description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 31
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 18
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 10
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 6
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 25
- 230000001939 inductive effect Effects 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 210000002865 immune cell Anatomy 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000036039 immunity Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 abstract description 20
- 238000009169 immunotherapy Methods 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 82
- 101710100111 SPARC Proteins 0.000 description 44
- 102100037599 SPARC Human genes 0.000 description 43
- 208000005718 Stomach Neoplasms Diseases 0.000 description 25
- 206010017758 gastric cancer Diseases 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 201000011549 stomach cancer Diseases 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 201000001441 melanoma Diseases 0.000 description 22
- 239000002671 adjuvant Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 15
- 206010036790 Productive cough Diseases 0.000 description 14
- 210000003802 sputum Anatomy 0.000 description 14
- 208000024794 sputum Diseases 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 208000000277 Splenic Neoplasms Diseases 0.000 description 11
- 201000002471 spleen cancer Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 101000881173 Mus musculus SPARC Proteins 0.000 description 5
- 238000009566 cancer vaccine Methods 0.000 description 5
- 229940022399 cancer vaccine Drugs 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 239000011651 chromium Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010070308 Refractory cancer Diseases 0.000 description 2
- 101150036757 SPARC gene Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101100494265 Caenorhabditis elegans best-15 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 1
- 101000856395 Homo sapiens Cullin-9 Proteins 0.000 description 1
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100036639 Myosin-11 Human genes 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-UHFFFAOYSA-N N-palmitoyldihydro-sphingosine Natural products CCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 206010058339 Splenitis Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000000370 laser capture micro-dissection Methods 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 101150095542 tap gene Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- -1 α-galactosyl Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Definitions
- the present invention relates to a novel peptide effective as a cancer vaccine for cancers that highly express SPARC such as gastric cancer, spleen cancer and malignant melanoma (melanoma), and treatment and Z or prevention of tumors containing the peptide. It is related with the medicine for.
- Gastric cancer has a higher prevalence in Asian countries such as Japan and China than in Europe and the United States. Gastric cancer can be detected at an early stage due to the spread of medical examinations, gastrointestinal endoscopy equipment, and advances in examination technology, and the number of patients is decreasing. However, it still accounts for the second largest cause of death of Japanese malignant neoplasms and still accounts for a high percentage of deaths.
- diffuse (skills) gastric cancer occurs in younger people than other gastric cancers (adenocarcinoma) and has a poor prognosis due to the tendency of cancer progression, metastasis, and peritoneal dissemination. It is urgent to establish a new treatment for Skills gastric cancer because it is often impossible to perform surgical resection at the time of diagnosis, and even if it can be removed, there are many recurrences after treatment.
- Melanoma is a type of skin cancer called malignant melanoma, and is very feared as a highly malignant cancer with a very strong tendency to infiltrate and metastasize.
- malignant melanoma a type of skin cancer
- melanin pigment a cell that produce melanin pigment
- melanocytes the ability to call these cells pigment cells (melanocytes).
- Melanoma is also increasing in frequency, particularly in whites, due to increased exposure to ultraviolet radiation due to the depletion of the ozone layer in the atmosphere due to environmental destruction.
- the incidence of melanoma in Japan is said to be about 1.5 to 2 per 100,000 population, and it is estimated that it will occur from 1500 to 2000 per year. In Europe and the United States, it is said that there are more than 10 outbreaks per 100,000 population, and in Australia, it is said that there are over 20 outbreaks per 100,000 population, the highest number in the world! For that reason, Westerners and Australians are interested in melanoma and paying attention to the occurrence of melanoma. Surprisingly, the incidence of melanoma has been increasing year by year both in foreign countries and in Japan. A recent survey shows that there are around 450 deaths per year from this disease in Japan.
- Melanoma occurs in people of all ages, but it occurs more often when people are over 40 years old, with the highest number in the 60s to 70s. Although the incidence of children is very small, it does not mean that they do not occur, and there is a tendency that young people in the 20s to 30s have been increasing recently. Gender tends to occur in both men and women, especially those who are more likely to be in either. The area where Japanese melanoma is likely to occur accounts for about 30%, where the sole of the foot (the back of the foot) is the most common. A feature of the Japanese is that they can do a lot on the toes and fingernails. In addition, like Westerners, body, hands, feet, face, It occurs on any skin, such as the head.
- cytotoxic (killer) T cells and helper T cell power are presented on the surface of cancer cells or antigen-presenting cells via HLA molecules. It was clarified that it recognizes a peptide formed by degrading a protein that is highly expressed specifically in cancer cells and shows an immune reaction that destroys cancer cells. In addition, many tumor antigen proteins and peptides derived from them that stimulate the immune response that attacks such cancers have been identified, and clinical application of antigen-specific tumor immunotherapy is underway. .
- HLA class I molecules are expressed on the surface of all nucleated cells of the body. Proteins produced in the cytoplasm and nucleus are bound to peptides produced by degradation in the cell, and the cell surface Expressed in On the surface of normal cells, peptides derived from normal self proteins are bound to HLA class I molecules, which are not identified and destroyed by T cells of the immune system. On the other hand, cancer cells are in the process of becoming cancerous and may be expressed in a large amount of protein with little or no expression in normal cells. Peptides produced by degrading proteins specifically expressed in cancer cells in the cytoplasm bound to HLA class I molecules and expressed on the surface of cancer cells are recognized by killer T cells. Only destroy cancer cells.
- cancer immunotherapy using a cancer-specific antigen.
- HLA class II molecules are mainly expressed on the surface of antigen-presenting cells, and bind to peptides derived from cancer-specific antigens that are formed by antigen-presenting cells taken from outside the cells and degraded in the cells. Expressed in Recognizing this, helper T-cells are activated and produce various site forces that activate other immunocompetent cells, thereby inducing or enhancing an immune response against the tumor.
- the present inventors previously analyzed the expression of 23,040 genes of genome-wide in gastric cancer tissue and normal tissue using a cDNA microarray. As a result, 11 out of 20 patients with diffuse invasive gastric cancer were more than 5 times (average ⁇ 10 million) in gastric cancer tissue compared to normal gastric mucosa, and the same as fc An acidic and ncn in cysteine (SPA RC) was identified.
- Figure 1 The SPARC gene showed mild expression in normal adipose tissue, mammary gland, ovary, spinal cord, testis, uterus, placenta, etc., but all were less than 5 times lower than normal gastric mucosa. ! It was expressed (Fig. 2).
- SPARC is highly expressed not only in diffuse invasive gastric cancer but also in spleen cancer and melanoma. Furthermore, the inventors have found that SPARC is secreted in the serum of melanoma patients and can be a useful tumor marker particularly for early detection of melanoma (Japanese Patent Application No. 2004-303688; and Clini cal Cancer). Research 11: 8079-8088, 2005).
- SPARC is a 43 KD acidic secreted protein consisting of 286 amino acids, rich in cysteine, and translocated to the nucleus during cell division. SPARC is also a protein involved in regulating cell growth by regulating the interaction between extracellular matrix proteins and cells. Since it is expressed in osteoblasts, platelets, and wound sites, it is thought to be involved in tissue repair and reconstruction. Furthermore, it has been reported that high expression in cancers such as melanoma and osteosarcoma, and tumor stromal cells, and that SPARC expression correlates with tumor prognosis, invasion or metastasis.
- Non-Patent Document 1 Ikuta Y et al., Clinical Cancer Research 11: 8079-8088, 2005.
- Patent Document 1 Japanese Patent Application 2004-303688
- the present invention has been implemented as a treatment method for tumors that highly express SPARC, such as diffuse invasive gastric cancer, spleen cancer, and melanoma! Metastatic cancer, which is difficult to treat with surgical therapy, chemotherapy, and radiation therapy.
- SPARC such as diffuse invasive gastric cancer, spleen cancer, and melanoma! Metastatic cancer
- the development of a means for immunotherapy that suppresses cancer growth by strengthening the immunity of cancer patients to cancer is an issue to be solved. That is, the present invention identifies a peptide derived from a S PARC protein that is highly expressed specifically for cancer and can induce a strong immune response to the above cancer without causing adverse events in cancer patients.
- the problem to be solved is to apply this to tumor immunotherapy.
- the present invention identifies human killer T cells that are reactive to tumors, and SPARC protein-derived peptides that can induce helper T cells, and targets tumors of various cancers that highly express SPARC. It is an issue to be solved to provide a means to enable immunotherapy.
- the present inventors have identified a gene SPARC that is highly expressed in diffuse invasive gastric cancer by cDNA microarray analysis of diffuse invasive gastric cancer. SPARC expression is also observed in some normal tissues, but is significantly lower than in cancerous areas.
- SPARC-specific killer T cells characterized for amino acid sequence of the peptide binding is identical to the most frequent HLA-A24 in Japanese mouse K d BALB / c mice expressing molecules were used.
- a peptide with a common amino acid sequence in both was synthesized with a binding motif common to human HLA-A 24 and mouse Kd . .
- mice Kd expression
- mice pretreated by the same immunization method it was examined whether the growth of transplanted mouse SPARC-expressing cancer cells was suppressed and the survival period was prolonged.
- mice pretreated by the same immunization method it was examined whether the growth of transplanted mouse SPARC-expressing cancer cells was suppressed and the survival period was prolonged.
- the possibility of adverse events appearing in the mice immunized with the peptides as observed in the autoimmune phenomenon As a result, the peptide consisting of the amino acid sequence shown in any of SEQ ID NOs: 1 to 3 destroyed SPARC-expressing cancer cells. It was confirmed that in mice immunized with these peptides, the proliferation of transplanted mouse SPARC-expressing cancer cells was suppressed and the survival period was prolonged.
- the present invention has been completed based on these findings.
- (B) A peptide having an amino acid sequence ability in which one or several amino acids are substituted or added to the peptide having an amino acid sequence ability shown in any one of SEQ ID NOs: 1 to 3, and having an ability to induce killer T cells.
- An immunity-inducing agent for cancer comprising at least one peptide according to (1).
- a pharmaceutical for tumor treatment and Z or prevention comprising at least one peptide according to (1).
- An agent for inducing an antigen-presenting cell having a tumor-reactive T cell-inducing ability comprising at least one peptide according to (1).
- An agent for inducing tumor-reactive T cells comprising at least one peptide according to (1).
- a drug for inducing an antigen-presenting cell having a tumor-reactive T cell-inducing ability comprising a gene encoding any of the following peptides.
- (B) A peptide having an amino acid sequence ability in which one or several amino acids are substituted or added to the peptide having an amino acid sequence ability shown in any one of SEQ ID NOs: 1 to 3, and having an ability to induce killer T cells.
- the peptide of the present invention is any of the following peptides.
- the peptide having the ability to induce cytotoxic T cells in the present specification means a peptide having T cell-inducing activity for stimulating killer T cells.
- the method for obtaining the peptide of the present invention 'production method is not particularly limited, and either a chemically synthesized peptide or a recombinant peptide prepared by a gene recombination technique may be used.
- the peptide of the present invention can be synthesized. Moreover, the peptide of this invention can also be synthesize
- DNA having a base sequence encoding the peptide, or a mutant or homologue thereof is obtained and introduced into a suitable expression system. Can be produced.
- the expression vector preferably has a force capable of autonomous replication in a host cell, or a position capable of expressing a gene encoding a peptide as long as it can be inserted into the host cell chromosome.
- the one containing a promoter is used.
- a transformant having a gene encoding the peptide of the present invention can be prepared by introducing the above expression vector into a host.
- the host may be any of bacteria, yeast, animal cells, and insect cells, and the introduction of the expression vector into the host may be performed by a known method according to each host.
- the transformant produced as described above is cultured, the peptide of the present invention is produced and accumulated in the culture, and the peptide of the present invention is collected from the culture, Recombinant peptides can be isolated.
- the medium for cultivating the product may be a natural medium or a synthetic medium as long as it contains a carbon source, a nitrogen source, inorganic salts, etc. that can be assimilated by the microorganism and can efficiently culture the transformant! / ⁇ .
- the culture conditions may be the same as those usually used for culturing the microorganism.
- ordinary methods for peptide isolation and purification may be used.
- one or several amino acids generally refers to 1 to: LO amino acids, preferably 1 to 8 amino acids, more preferably 1 to 5 amino acids, especially Preferably it means 1 to 3 amino acids (for example 1, 2 or 3 amino acids).
- the peptide consisting of the amino acid sequence shown in any one of SEQ ID NOS: 1 to 3 is any one of SEQ ID NOS: 1 to 3.
- a person skilled in the art can appropriately produce or obtain the amino acid sequence based on the amino acid sequence information described in. That is, in the amino acid sequence shown in any one of SEQ ID NOs: 1 to 3, a peptide having an amino acid sequence in which one or several amino acids are substituted or added, and having the ability to induce cytotoxic T cells is the above-mentioned chemical synthesis. It can also be produced by any method known to those skilled in the art, such as genetic engineering techniques or mutagenesis.
- site-directed mutagenesis which is one of genetic engineering techniques, is useful because it can introduce a specific mutation at a specific position.
- Molecular Cloning A laboratory Mannual, 2 Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY., 1989, hereinafter abbreviated as Molecular Cloning 2nd Edition), Current Protocols in Molecular Biology, Supplement 1-38, John Wiley & Sons (1987-1997) Current 'protocols' in 'molecular' (abbreviated as biology), etc.
- the peptide of the present invention described above can induce immunity against cancer, as shown in Examples below. Therefore, according to this invention, the immunity induction agent with respect to cancer containing the peptide of this invention is provided.
- the immunity-inducing agent for cancer of the present invention can induce killer T cells, helper T cells, or an immune cell population containing these by using in vitro, etha vivo or in vivo, preferably etha vivo. Can immunize against cancer wear.
- the present invention also relates to an antibody that recognizes part or all of the above-described peptide of the present invention as an epitope (antigen), and killer T cells induced using the peptide by etha vivo or in vitro stimulation.
- killer T cells are known to exhibit stronger antitumor activity than antibodies.
- the antibody of the present invention may be a polyclonal antibody or a monoclonal antibody, and can be produced by a conventional method.
- a polyclonal antibody is obtained by immunizing a mammal or a bird using the peptide of the present invention as an antigen, collecting blood from the mammal or bird, and separating and purifying the antibody from the collected blood.
- mammals such as mice, mice, mussels, guinea pigs, chickens, rats, rabbits, dogs, goats, hidges, horses, horses, etc., or birds can be immunized. Methods for immunization are known to those skilled in the art.
- an antigen may be administered 2 to 3 times, for example, at intervals of 7 to 30 days. The dose can be about 0.05 to 2 mg of antigen per dose, for example.
- the administration route is not particularly limited, and subcutaneous administration, intradermal administration, intraperitoneal administration, intravenous administration, intramuscular administration, and the like can be appropriately selected.
- the antigen can be used by dissolving in a buffer containing a suitable adjuvant, for example, a complete buffer containing a commonly used adjuvant such as Freund's complete adjuvant or hydroxyaluminum hydroxide.
- booster immunization can be performed using, for example, 100 g to 1000 g of antigen.
- the immunized mammal or avian animal is also blood collected, and the blood (polyclonal antiserum) is centrifuged, precipitated using, for example, ammonium sulfate or polyethylene glycol.
- the polyclonal antibody that recognizes the peptide of the present invention can be obtained by separation and purification by conventional methods such as chromatography, gel filtration chromatography, ion exchange chromatography, affinity chromatography and the like.
- a monoclonal antibody can be obtained by preparing a hybridoma.
- hypridoma can be obtained by cell fusion between an antibody-producing cell and a myeloma cell line.
- the A hyperidoma producing the monoclonal antibody of the present invention can be obtained by the following cell fusion method.
- spleen cells As antibody-producing cells, spleen cells, lymph node cells, B lymphocytes and the like from immunized animals are used.
- the peptide of the present invention is used as the antigen.
- Mice, rats, and the like can be used as immunized animals, and antigens are administered to these animals by conventional methods.
- an animal is administered by injecting a suspension or emulsion of an adjuvant such as complete Freund's adjuvant or incomplete Freund's adjuvant and the peptide of the present invention as an antigen several times subcutaneously, intradermally, intraperitoneally, etc. Immunize.
- spleen cells are obtained from the immunized animal as antibody-producing cells, and these and myeloma cells are fused by a known method (G. Kohler et al., Nature, 25 6 495 (1975)) to prepare hyperidoma. Can be produced.
- Examples of myeloma cell lines used for cell fusion include P3X63Ag8, P3U1 strain, and Sp2Z0 strain in mice.
- a fusion promoter such as polyethylene glycol or Sendai virus is used, and hypoxanthine 'aminopterin' thymidine (HAT) medium is used in accordance with a conventional method for selection of the hyperidoma after cell fusion.
- HAT hypoxanthine 'aminopterin' thymidine
- Hypridoma obtained by cell fusion is cloned by a limiting dilution method or the like.
- cell lines producing monoclonal antibodies that specifically recognize the peptide of the present invention can be obtained by performing screening by an enzyme immunoassay using the peptide of the present invention.
- the hybridoma is cultured by a normal cell culture method or ascites formation method, and the monoclonal antibody is then cultured from the culture supernatant or ascites. If you refine it. Purification of the monoclonal antibody from the culture supernatant or ascites can be performed by a conventional method. For example, ammonium sulfate fractionation, gel filtration, ion exchange chromatography, and affinity chromatography can be used in appropriate combinations.
- antibody fragments are also within the scope of the present invention.
- antibody fragments include F (ab ′) 2 fragments, Fab ′ fragments, and the like.
- the present invention also provides killer T induced by in vitro stimulation using the peptides of the present invention.
- Cells, helper T cells, or immune cell populations containing them For example, when peripheral blood lymphocytes and tumor-infiltrating lymphocytes are stimulated in vitro with the peptide of the present invention, activated sputum cells showing tumor reactivity are induced, and the activated sputum cells are adopted as cancer adoptive immunotherapy. Can be used effectively.
- the peptide of the present invention can be expressed in vivo or in vitro in cells that are strong antigen-presenting cells, and the antigen peptide-expressing cells can be administered to induce an immune response against the tumor. .
- killer sputum cells, helper sputum cells, or immune cell populations containing these can be induced by ethaso-vivo or in vitro stimulation using the peptide of the present invention and an immunostimulant.
- immunostimulant include cell growth factor and cytokin.
- the tumor By transferring the killer sputum cells, helper sputum cells, or immune cell population containing these cells obtained as described above into the body, the tumor can be suppressed, and cancer can be prevented and / or treated or treated. It is possible.
- killer sputum cells, helper sputum cells, or immune cell populations containing these can be prepared that can suppress tumor growth. Therefore, according to the present invention, there is provided a cell culture medium containing tumor-reactive mouse cells and the peptide of the present invention. By using this cell culture solution, it is possible to produce killer sputum cells, helper sputum cells, or immune cell populations containing these that can suppress tumors. Furthermore, according to the present invention, there is also provided a cell culture kit for producing a killer sputum cell, a helper sputum cell, or an immune cell population containing these, comprising the above cell culture medium and a cell culture container.
- the peptide of the present invention can induce cancer cell-specific killer cells, it can be expected as an agent for treating or preventing cancer.
- a BCG bacterium transformed with this recombinant DNA containing the gene encoding the peptide of the present invention into an appropriate vector, or a vaccinia virus integrated with the DNA encoding the peptide of the present invention in the genome Such viruses can be effectively used as a live vaccine for the treatment and prevention of human cancer.
- the dose and method of administration of cancer vaccine are the same as those for normal vaccination and BCG vaccine.
- the DNA encoding the peptide of the present invention (as it is or in the form of plasmid DNA incorporated into an expression vector), the recombinant virus or recombinant bacteria containing the DNA as it is or dispersed in an adjuvant
- the peptide of the present invention can be administered as a cancer vaccine in a state dispersed with adjuvant.
- adjuvants examples include Freund's incomplete adjuvant, BCG, trehalose dimycolate (TDM), lipopolysaccharide (LPS), myoban adjuvant, silica adjuvant, and the like. It is preferable to use Freund's incomplete adjuvant (IFA) because of its induction ability.
- IFA Freund's incomplete adjuvant
- the type of cancer referred to in the present specification is not particularly limited, and specific examples include stomach cancer, colon cancer, esophageal cancer, spleen cancer, liver cancer, gallbladder cancer, bile duct cancer, lung cancer, breast cancer, thyroid cancer, melanoma ( Malignant melanoma), skin cancer, osteosarcoma, pheochromocytoma, head and neck cancer, brain tumor, chronic myelogenous leukemia, acute myelogenous leukemia, malignant lymphoma, kidney cancer, bladder cancer, prostate cancer, testicular cancer, uterine cancer, Examples include ovarian cancer or soft tissue sarcoma. Among these, cancers that highly express SPARC such as gastric cancer (particularly diffuse invasive gastric cancer), spleen cancer, or melanoma (malignant melanoma) are listed. I can make it.
- the peptide of the present invention can induce killer T cells or helper T cells specific to cancer cells as T cell epitopes, it is useful as a prophylactic / therapeutic agent for human cancer.
- the antibody of the present invention is also useful as a prophylactic / therapeutic agent for human cancer if it can inhibit the activity of SPARC, which is a cancer antigen.
- the peptide or antibody of the present invention may be administered as an injection as it is, or together with a pharmaceutically acceptable carrier and Z or diluent, with the following adjuvant as necessary. Alternatively, it may be administered by percutaneous absorption from the mucous membrane by a method such as spraying.
- the carrier referred to here is, for example, human serum albumin, and examples of the diluent include PBS, distilled water and the like.
- the dosage is not limited to this range, but can be administered so that the dose of the peptide or antibody of the present invention per adult is, for example, in the range of 0.0 lmg to 100 mg per dose.
- the form of the preparation is not particularly limited, either lyophilized or sugar or other excipients. In addition, it can be granulated.
- MDP muramyl dipeptide
- other bacterial cell components such as BCG bacteria, Nature, vol. ISCOM described in J. Immunol. vol. 148, pl438 (1992), ribosomes, aluminum hydroxide, and the like.
- immunostimulants such as lentinan, schizophyllan, and picibanil can be used as adjuvants.
- IL-2, IL-4, IL12, IL-1, IL-6, TNF and other T cell proliferation, cyto force-in to enhance sorting, etc., and ⁇ -galactosyl that activates NKT cells Ceramid can be used as an adjuvant such as CpG or lipopolysaccharide (LPS), which binds to ToU-like receptors and activates the innate immune system.
- LPS lipopolysaccharide
- the antigen peptide is added to the cells collected from HLA-A24-positive patients or cells derived from other HLA-A24-positive cells in a test tube, and the antigen is presented.
- killer T cells can be induced in a test tube and then returned to the patient's blood vessel by adding the peptide to patient peripheral blood lymphocytes and culturing in vitro.
- Such treatment by cell transfer has already been carried out as a cancer treatment method, which is well known among those skilled in the art.
- tumor-reactive T cells are induced, and as a result, an antitumor effect can be expected.
- lymphocytes are stimulated with the peptide of the present invention in vivo or in vitro, activated T cells are induced, and can be effectively used for adoptive immunotherapy by injecting the activated T cells into the affected area.
- the extracted cancerous and non-cancerous tissues of patients with diffuse invasive gastric cancer were separated by laser capture microdissection and extracted from each tissue. Reverse transcription from these RNAs
- the cancer region cDNA was fluorescently labeled with Cy5 and the non-cancerous region cDNA was fluorescently labeled with Cy3 and mixed to obtain the target DNA.
- non-specific binding is washed away and the fluorescence image after hybridization is captured using a CCD camera or fluorescence scanner.
- the ratio (R / G) of each fluorescence intensity was calculated and shown as a gene expression profile. Furthermore, by comparing the expression of 23,040 genes in 20 cancerous and noncancerous patients with diffuse invasive gastric cancer, in many cases the expression ratio of cancerous / noncancerous is 5 15 types of the above genes were selected (Fig. 1).
- the following peptides were selected from peptide parts having the same amino acid sequence in human and mouse SPARC having 95% homology. Based on known information about commonly observed amino acid sequences of peptides that bind strongly to both human HLA-A24 and mouse Kd molecules, we searched for the entire amino acid sequence of SPARC molecules and found binding affinity for both molecules. A repertoire of peptides presumed to be high was selected using a computer program. As a result, four types of candidate peptides were determined (Table 1).
- SPARC Kd-1 SEQ ID NO: 1
- SPARC Kd-3 SEQ ID NO: 2
- SPARC Kd-4 SEQ ID NO: 3
- Bone marrow cell power derived from BALB / c bone marrow GM-CSF was used to induce bone marrow cell derived rod cells (BM-DC).
- BM-DC bone marrow cell derived rod cells
- the BM-DC obtained in this way was cultured for 2 hours at a concentration of 10 ⁇ 4 with the mixture of the four peptides determined above, and then 5 x 10 5 per animal was administered intraperitoneally. did.
- the mice were immunized twice in the same manner at intervals of 1 week, and the spleen cells of the mice were collected and used for detection of killer sputum cells.
- the spleen cell force was removed from the CD4 + T cells using the MACS beads after the spleen was collected.
- BM-DC bone marrow-derived rod-shaped cells
- T2K d cells were set as target tumor cells to be injured by killer T cells.
- T2K d cells are cell lines in which a Kd gene is introduced into a mouse T2 cell line that lacks TAP gene expression. Peptide force added from outside due to TAP deficiency Only when it has the property of binding to SMHC class I molecule, the complex of MHC class I molecule and peptide is expressed on the cell surface.
- the RL male 1 cell line is a T cell leukemia cell derived from BALB / c mice. Neither cell expresses SPARC.
- the Meth A and BALB / 3T3 cell lines express SPARC in fibrosarcoma and fibroblast cell lines derived from BALB / c mice.
- mice After culturing BM-DC with 10 ⁇ SPARC K d- 1,3,4 mixed peptide for 2 hours, 5 ⁇ 10 5 cells were administered intraperitoneally. Seven days after immunizing mice a total of two times in the same manner with peptide-loaded BM-DC at one week intervals, the mouse fibrosarcoma cell line Meth A (l X 10 6 ) that highly expresses mouse SPARC was obtained. Implanted subcutaneously, tumor growth and mouse survival It was investigated.
- HLA-A24 (A * 2402) is the most frequent HLA class I allele owned by about 60% of Japanese.
- the amino acid sequence of the peptide that binds to the BALB / c mouse Kd molecule, corresponding to the HLA class I molecule, is very similar to that of the peptide that binds to human HLA-A24. Therefore, when BALB / c mice are immunized with a peptide, the peptide binds to the Kd molecule and induces killer T cells, which destroy cancer cells that express the complex of the peptide and Kd molecule. Has shown that the peptide can bind to HLA-A24 and induce human 'killer T cells, which also destroy cancer cells.
- the peptides presented in the present invention can be applied to immunotherapy of diffuse invasive gastric cancer, spleen cancer and melanoma patients who possess HLA-A24. Suppressing progress is expected to improve patient quality of life.
- FIG. 1 shows the best 15 genes highly expressed in gastric cancer tissues compared to normal gastric mucosa, as determined by cDNA microarray analysis of 20 patients with diffuse invasive gastric cancer. The degree of expression in individual cases is shown. Among these, considering the results of cDNA microarray analysis of normal tissues shown below, Secreted protein acidic and rich in cysteine (SPARC), which is highly expressed specifically in the cancerous part, is the most common in diffuse invasive gastric cancer. Selected as an ideal cancer-specific antigen.
- SPARC secreted protein acidic and rich in cysteine
- Figure 2 shows the analysis of SPARC expression in 25 adult major organs and 4 embryonic organs using cDNA microarrays. The expression of the SPARC gene is also observed in some normal tissues, but the level of expression was significantly lower than that in the cancerous part.o
- Fig. 3 shows the results of SPARC induced by CTL induced with mouse Kd- restricted SPARC Kd- 1, Kd- 3, or Kd- 4 epitope peptide in BALB / c mice. Positive tumor cell wound Indicates harm.
- Fig. 4 shows the results of pre-administration of bone marrow dendritic cells (BM-DC) to BALB / c mice loaded with SPARC Kd- 1, Kd- 3 and Kd- 4 peptides. Inhibition of growth and survival of Meth A cancer cells implanted subcutaneously.
- BM-DC bone marrow dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT07745372T ATE509096T1 (de) | 2006-06-16 | 2007-06-15 | Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält |
MX2008015939A MX2008015939A (es) | 2006-06-16 | 2007-06-15 | Peptidos antigeneticos de rechazo de tumor derivados de sparc y medicamentos que comprenden los mismos. |
CN200780022547XA CN101472943B (zh) | 2006-06-16 | 2007-06-15 | 来自sparc的癌排斥抗原肽以及含有该肽的药物 |
AU2007259667A AU2007259667B2 (en) | 2006-06-16 | 2007-06-15 | SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same |
CA 2655361 CA2655361C (en) | 2006-06-16 | 2007-06-15 | Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same |
US12/304,350 US8053557B2 (en) | 2006-06-16 | 2007-06-15 | SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same |
BRPI0713731A BRPI0713731B8 (pt) | 2006-06-16 | 2007-06-15 | agente indutor de imunidade direcionado contra cânceres, medicamento para tratar e/ou prevenir tumores, e, agente para induzir células |
JP2008521269A JP5150849B2 (ja) | 2006-06-16 | 2007-06-15 | Sparc由来の癌拒絶抗原ペプチド及びこれを含む医薬 |
EP20070745372 EP2030984B1 (en) | 2006-06-16 | 2007-06-15 | Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same |
KR1020097000778A KR101408173B1 (ko) | 2006-06-16 | 2007-06-15 | Sparc 유래의 암 거절항원 펩티드 및 이를 포함하는 의약 |
IL195831A IL195831A (en) | 2006-06-16 | 2008-12-10 | Antigen peptides that repel SPARC-derived tumors and agents that induce cancer against cancers containing these peptides |
HK09105810A HK1128924A1 (en) | 2006-06-16 | 2009-06-29 | Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc |
US13/243,259 US8470968B2 (en) | 2006-06-16 | 2011-09-23 | SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same |
US13/901,194 US9120842B2 (en) | 2006-06-16 | 2013-05-23 | SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006167724 | 2006-06-16 | ||
JP2006-167724 | 2006-06-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/304,350 A-371-Of-International US8053557B2 (en) | 2006-06-16 | 2007-06-15 | SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same |
US13/243,259 Division US8470968B2 (en) | 2006-06-16 | 2011-09-23 | SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007145318A1 true WO2007145318A1 (ja) | 2007-12-21 |
Family
ID=38831831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/062117 WO2007145318A1 (ja) | 2006-06-16 | 2007-06-15 | Sparc由来の癌拒絶抗原ペプチド及びこれを含む医薬 |
Country Status (15)
Country | Link |
---|---|
US (3) | US8053557B2 (ja) |
EP (1) | EP2030984B1 (ja) |
JP (1) | JP5150849B2 (ja) |
KR (1) | KR101408173B1 (ja) |
CN (3) | CN105418751B (ja) |
AT (1) | ATE509096T1 (ja) |
AU (1) | AU2007259667B2 (ja) |
BR (1) | BRPI0713731B8 (ja) |
CA (1) | CA2655361C (ja) |
ES (1) | ES2365077T3 (ja) |
HK (1) | HK1128924A1 (ja) |
IL (1) | IL195831A (ja) |
MX (1) | MX2008015939A (ja) |
RU (1) | RU2451521C2 (ja) |
WO (1) | WO2007145318A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010137295A1 (en) * | 2009-05-26 | 2010-12-02 | Oncotherapy Science, Inc. | Cdc45l peptides and vaccines including the same |
JP2013091645A (ja) * | 2007-02-21 | 2013-05-16 | Oncotherapy Science Ltd | 腫瘍関連抗原を発現する癌に対するペプチドワクチン |
JP2013522235A (ja) * | 2010-03-11 | 2013-06-13 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Sparc血管新生領域及びその使用法 |
RU2491085C2 (ru) * | 2008-12-05 | 2013-08-27 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Sparc-связующие пептиды и их применение |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103242428B (zh) | 2005-08-09 | 2015-04-15 | 肿瘤疗法.科学股份有限公司 | 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物 |
CA2655361C (en) | 2006-06-16 | 2014-10-07 | Kumamoto University | Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same |
TWI580431B (zh) * | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗 |
WO2011035274A1 (en) * | 2009-09-18 | 2011-03-24 | Abraxis Bioscience, Llc | Use of the sparc microenvironment signature in the treatment of cancer |
KR20130086546A (ko) | 2010-06-03 | 2013-08-02 | 아브락시스 바이오사이언스, 엘엘씨 | 암 치료에 있어 sparc 미세환경 시그니처의 용도 |
RU2634862C2 (ru) | 2011-05-19 | 2017-11-07 | Торэй Индастриз, Инк. | Агент, индуцирующий иммунитет |
JP7195621B2 (ja) * | 2018-01-09 | 2022-12-26 | 学校法人藤田学園 | 細胞殺傷剤 |
MY182816A (en) * | 2018-02-15 | 2021-02-05 | National Univ Corporation Asahikawa Medical Univ | Cancer antigen peptide |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004303688A (ja) | 2003-04-01 | 2004-10-28 | Matsushita Electric Works Ltd | 放電灯点灯装置 |
JP2006503575A (ja) * | 2002-10-25 | 2006-02-02 | オンコセラピー・サイエンス株式会社 | びまん型胃癌を診断する方法 |
WO2006043362A1 (ja) * | 2004-10-19 | 2006-04-27 | Kumamoto University | 悪性黒色腫(メラノーマ)の新規な診断キット |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE207366T1 (de) * | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
JP2000023673A (ja) * | 1998-07-13 | 2000-01-25 | Ajinomoto Co Inc | ヒト胃癌抗原遺伝子および胃癌抗原蛋白質 |
WO2002000677A1 (en) * | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
CA2448253A1 (en) * | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
EP1536006B1 (en) | 2002-08-30 | 2011-08-24 | Medinet Co., Ltd. | Cancer antigens and utilization thereof |
EP1684076B1 (en) | 2003-10-29 | 2008-12-31 | Kumamoto Technology & Industry Foundation | Diagnostic method for malignant melanoma |
CN103242428B (zh) | 2005-08-09 | 2015-04-15 | 肿瘤疗法.科学股份有限公司 | 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物 |
CA2655361C (en) | 2006-06-16 | 2014-10-07 | Kumamoto University | Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same |
-
2007
- 2007-06-15 CA CA 2655361 patent/CA2655361C/en active Active
- 2007-06-15 AT AT07745372T patent/ATE509096T1/de active
- 2007-06-15 CN CN201610034435.7A patent/CN105418751B/zh active Active
- 2007-06-15 KR KR1020097000778A patent/KR101408173B1/ko active IP Right Grant
- 2007-06-15 BR BRPI0713731A patent/BRPI0713731B8/pt not_active IP Right Cessation
- 2007-06-15 CN CN200780022547XA patent/CN101472943B/zh active Active
- 2007-06-15 WO PCT/JP2007/062117 patent/WO2007145318A1/ja active Application Filing
- 2007-06-15 RU RU2009101191/10A patent/RU2451521C2/ru active
- 2007-06-15 AU AU2007259667A patent/AU2007259667B2/en not_active Ceased
- 2007-06-15 US US12/304,350 patent/US8053557B2/en not_active Expired - Fee Related
- 2007-06-15 JP JP2008521269A patent/JP5150849B2/ja active Active
- 2007-06-15 ES ES07745372T patent/ES2365077T3/es active Active
- 2007-06-15 EP EP20070745372 patent/EP2030984B1/en active Active
- 2007-06-15 MX MX2008015939A patent/MX2008015939A/es active IP Right Grant
- 2007-06-15 CN CN201310236439.XA patent/CN103435683B/zh active Active
-
2008
- 2008-12-10 IL IL195831A patent/IL195831A/en active IP Right Grant
-
2009
- 2009-06-29 HK HK09105810A patent/HK1128924A1/xx not_active IP Right Cessation
-
2011
- 2011-09-23 US US13/243,259 patent/US8470968B2/en active Active
-
2013
- 2013-05-23 US US13/901,194 patent/US9120842B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006503575A (ja) * | 2002-10-25 | 2006-02-02 | オンコセラピー・サイエンス株式会社 | びまん型胃癌を診断する方法 |
JP2004303688A (ja) | 2003-04-01 | 2004-10-28 | Matsushita Electric Works Ltd | 放電灯点灯装置 |
WO2006043362A1 (ja) * | 2004-10-19 | 2006-04-27 | Kumamoto University | 悪性黒色腫(メラノーマ)の新規な診断キット |
Non-Patent Citations (15)
Title |
---|
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS, pages: 1 - 38 |
"Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY, article "Molecular Cloning: A laboratory Manual" |
AKIYAMA Y. ET AL.: "Identification, of HLA-A24-Restricted CTL Epitope Encoded by the Matrix Protein pp65 of Human Cytomegalovirus", IMMUNOL. LETT., vol. 83, no. 1, 2002, pages 21 - 30, XP003020538 * |
CLINICAL CANCER RESEARCH, vol. 11, 2005, pages 8079 - 8088 |
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY |
G KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
IKUTA Y. ET AL.: "Gan Kogen SPARC o Mochiita Gan Men'eki Ryoho Model no Kakuritsu", DAI 10 KAI SOCIETY FOR FUNDAMENTAL CANCER IMMUNOLOGY SOKAI SHOROKU, 30 June 2006 (2006-06-30), pages 58, XP003020539 * |
IKUTA Y. ET AL.: "Gan Tokuiteki ni Kohatsugen suru SPARC o Hyoteki to shita Mouse Gan Men'eki Ryoho Model no Kochiku", DAI 65 KAI MANNAUL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, 28 August 2006 (2006-08-28), pages 62 + ABSTR. NO. 0-147, XP003020540 * |
IKUTA Y. ET AL.: "Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreated Protein Acidic and Rich in Cysteine and Glypican-3 Levels", CLIN. CANCER RES., vol. 11, no. 22, 2005, pages 8079 - 8088, XP002456096 * |
J. IMMUNOL., vol. 148, 1992, pages 1438 |
KOMORI H. ET AL.: "Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma", CLIN. CANCER RES., vol. 12, no. 9, 2006, pages 2689 - 2697, XP003020537 * |
NAKATSURA T. ET AL.: "Mouse Homologue of a Novel Huma Oncofetal Antigen Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice", CLIN. CANCER RES., vol. 10, no. 24, 2004, pages 8630 - 8640, XP003016234 * |
NAKATSURA,T ET AL., CLIN CANCER RES, vol. 10, 2004, pages 8630 - 8640 |
NATURE, vol. 344, 1990, pages 873 |
WANG C.S. ET AL.: "Overexpression of SPARC Gene in Human Gastric Carcinoma and Its Clinic-Pathologic Significance", BR. J. CANCER, vol. 91, no. 11, 2004, pages 1924 - 1930, XP003020536 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013091645A (ja) * | 2007-02-21 | 2013-05-16 | Oncotherapy Science Ltd | 腫瘍関連抗原を発現する癌に対するペプチドワクチン |
JP2013116895A (ja) * | 2007-02-21 | 2013-06-13 | Oncotherapy Science Ltd | 腫瘍関連抗原を発現する癌に対するペプチドワクチン |
RU2491085C2 (ru) * | 2008-12-05 | 2013-08-27 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Sparc-связующие пептиды и их применение |
CN106905429A (zh) * | 2008-12-05 | 2017-06-30 | 阿布拉西斯生物科学有限责任公司 | 结合SPARC的scFv |
WO2010137295A1 (en) * | 2009-05-26 | 2010-12-02 | Oncotherapy Science, Inc. | Cdc45l peptides and vaccines including the same |
CN102459589A (zh) * | 2009-05-26 | 2012-05-16 | 肿瘤疗法科学股份有限公司 | Cdc45l肽及包含它的疫苗 |
JP2012527867A (ja) * | 2009-05-26 | 2012-11-12 | オンコセラピー・サイエンス株式会社 | Cdc45lペプチドおよびそれを含むワクチン |
US8586547B2 (en) | 2009-05-26 | 2013-11-19 | Oncotherapy Science, Inc. | CDC45L peptides and vaccines including the same |
CN102459589B (zh) * | 2009-05-26 | 2013-12-25 | 肿瘤疗法科学股份有限公司 | Cdc45l肽及包含它的疫苗 |
CN103694315A (zh) * | 2009-05-26 | 2014-04-02 | 肿瘤疗法科学股份有限公司 | Cdc45l肽及包含它的疫苗 |
CN103694315B (zh) * | 2009-05-26 | 2015-07-29 | 肿瘤疗法科学股份有限公司 | Cdc45l肽及包含它的疫苗 |
JP2013522235A (ja) * | 2010-03-11 | 2013-06-13 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Sparc血管新生領域及びその使用法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5150849B2 (ja) | Sparc由来の癌拒絶抗原ペプチド及びこれを含む医薬 | |
JP5299942B2 (ja) | HLA−A2陽性者用glypican−3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬 | |
JP5909767B2 (ja) | Foxm1ペプチドおよびこれを含む薬剤 | |
JP5291641B2 (ja) | 癌抗原及びその利用 | |
JP2013047230A (ja) | Hla−a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780022547.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07745372 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 195831 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2008/015939 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2655361 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008521269 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007259667 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007745372 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097000778 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 252/CHENP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009101191 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2007259667 Country of ref document: AU Date of ref document: 20070615 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12304350 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0713731 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081215 |